© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
ARTICLE |
Cellular Effects and Antitumor Activity of RET Inhibitor RPI-1 on MEN2A-Associated Medullary Thyroid Carcinoma
Affiliations of authors: Preclinical Chemotherapy and Pharmacology Unit (G. Cuccuru, CL, G. Cassinelli, G. Pratesi, MT, G. Petrangolini, DL, CZ, FZ), and Nuclear Medicine Unit (ES, AM), Istituto Nazionale Tumori, Milan, Italy.
Correspondence to: Cinzia Lanzi, PhD, Department of Experimental Oncology, Preclinical Chemotherapy and Pharmacology Unit, Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy (e-mail: cinzia.lanzi{at}istitutotumori.mi.it)
Background: The RET proto-oncogene encodes a receptor tyrosine kinase. RET oncogenes arise through sporadic and inherited gene mutations and are involved in the etiopathogenesis of medullary thyroid carcinoma, a cancer that responds poorly to conventional chemotherapy. Medullary thyroid carcinoma is a component of multiple endocrine neoplasia type 2 or MEN2 syndromes. Methods: We investigated the cellular effects of RPI-1, a novel 2-indolinone Ret tyrosine kinase inhibitor on cells that express RET C634 oncogenic mutants common in the MEN2A syndrome: NIH3T3 fibroblasts transfected with RETC634R and human medullary thyroid carcinoma TT cells that express endogenous RETC634W. RPI-1 antiproliferative activity was determined by cell proliferation and anchorage-independent growth assays. Expression and phosphorylation of Ret and of proteins involved in downstream signaling pathways were examined by immunoblotting. Antitumor activity of oral RPI-1 treatment was tested by using two dosing levels in nude mice bearing subcutaneous TT xenograft tumors. All statistical tests were two-sided. Results: The RPI-1 IC50 value for cell proliferation was 3.6 µM (95% confidence interval [CI] = 1.8 to 5.4 µM) in NIH3T3 cells expressing the Ret mutant compared with 16 µM (95% CI = 12.3 to 19.7 µM) in non-transfected NIH3T3 cells, and that for colony formation in soft agar was 2.4 µM (95% CI = 0.8 to 4.0 µM) and 26 µM (95% CI = 17 to 35 µM) in RET mutant–transfected and H-RAS-transfected NIH3T3 cells, respectively. In NIH3T3 cells expressing the Ret mutant, Ret protein and tyrosine phosphorylation were undetectable after 24 hours of RPI-1 treatment. In TT cells, RPI-1 inhibited proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLC
, ERKs and AKT. In mice, oral daily RPI-1 treatment inhibited the tumor growth of TT xenografts by 81% (P<.001 versus control mice) and reduced the plasma levels of the specific biomarker calcitonin (P = .01 versus control mice). Twenty-five percent of RPI-1-treated mice were tumor-free. Conclusions: Ret oncoproteins represent exploitable targets for therapeutic intervention in MEN2A-associated medullary thyroid carcinoma. The antitumor efficacy and oral bioavailability of RPI-1 support its therapeutic potential.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Evolving Strategies for Targeted Cancer Therapy—Past, Present, and Future
- Samuel A. Wells and Joseph R. Nevins
J Natl Cancer Inst 2004 96: 980-981.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  I. Plaza-Menacho, L. Mologni, E. Sala, C. Gambacorti-Passerini, A. I. Magee, T. P. Links, R. M. W. Hofstra, D. Barford, and C. M. Isacke Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting J. Biol. Chem., October 5, 2007; 282(40): 29230 - 29240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Johanson, H. Ahlman, P. Bernhardt, S. Jansson, L. Kolby, F. Persson, G. Stenman, C. Sward, B. Wangberg, M. Stridsberg, et al. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis Endocr. Relat. Cancer, June 1, 2007; 14(2): 433 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cassinelli, C. Lanzi, G. Petrangolini, M. Tortoreto, G. Pratesi, G. Cuccuru, D. Laccabue, R. Supino, S. Belluco, E. Favini, et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol. Cancer Ther., September 1, 2006; 5(9): 2388 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Carlomagno, S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S. M. Wilhelm, and M. Santoro BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, March 1, 2006; 98(5): 326 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Borrello, L. Alberti, A. Fischer, D. Degl'Innocenti, C. Ferrario, M. Gariboldi, F. Marchesi, P. Allavena, A. Greco, P. Collini, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene PNAS, October 11, 2005; 102(41): 14825 - 14830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Santoro, R. M. Melillo, F. Carlomagno, G. Vecchio, and A. Fusco Minireview: RET: Normal and Abnormal Functions Endocrinology, December 1, 2004; 145(12): 5448 - 5451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Wells and J. R. Nevins Evolving Strategies for Targeted Cancer Therapy--Past, Present, and Future J Natl Cancer Inst, July 7, 2004; 96(13): 980 - 981. [Full Text] [PDF]
|
|